BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Elahere (Mirvetuximab soravtansine) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Elahere (Mirvetuximab soravtansine)\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05456685-11140@assetmemo.bio
DTSTAMP:20261121T010017Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT05456
 685)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2\, Ovarian Cancer.
 \nStudy: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line 
 Treatment of Folate Receptor Alpha (FRα) Expressing\, Platinum-sensitive 
 Epithelial Ovarian Cancer\nEstimated primary completion: November 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/mirvetuximab-soravtansi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5456685
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06365853-11140@assetmemo.bio
DTSTAMP:20261121T010017Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT06365
 853)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2\, Ovarian Cancer.
 \nStudy: A Study of Ocular Toxicity Evaluation and Mitigation During Treat
 ment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian
  Cancer With High Folate Receptor-Alpha Expression\nEstimated primary comp
 letion: February 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/mirvetuximab-soravtansine#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06365853
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05445778-11140@assetmemo.bio
DTSTAMP:20261121T010017Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 3 readout est. (NCT05445
 778)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 3\, Ovarian Cancer.
 \nStudy: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as 
 Maintenance in Platinum-sensitive Epithelial Ovarian\, Fallopian Tube\, or
  Peritoneal Cancer\nEstimated primary completion: April 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05445778
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07741630-11140@assetmemo.bio
DTSTAMP:20261121T010017Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT07741
 630)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2\, Ovarian Cancer.
 \nStudy: Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Re
 sistant Recurrent Ovarian Cancer\nEstimated primary completion: 30 June 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/mirvetuximab-sora
 vtansine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07741630
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04606914-11140@assetmemo.bio
DTSTAMP:20261121T010017Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT04606
 914)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2\, Ovarian Cancer.
 \nStudy: Study of Carboplatin and Mirvetuximab Soravtansine in First-Line 
 Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Sta
 ge Ovarian\, Fallopian Tube or Primary Peritoneal Cancer\nEstimated primar
 y completion: July 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/mirvetuximab-soravtansine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04606914
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07825753-11140@assetmemo.bio
DTSTAMP:20261121T010017Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT07825
 753)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2.\nStudy: Protein-
 Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer
 \nEstimated primary completion: 1 September 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07825753
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07934121-11140@assetmemo.bio
DTSTAMP:20261121T010017Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT07934
 121)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2\, Ovarian Cancer.
 \nStudy: MIRV in Combination With Suvemcitug for Partially Platinum-Sensit
 ive Ovarian Cancer\nEstimated primary completion: 30 June 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07934121
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059845-11140@assetmemo.bio
DTSTAMP:20261121T010017Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT07059
 845)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2\, Ovarian Cancer.
 \nStudy: A Study to Assess Adverse Events and Change in Disease Activity o
 f Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansi
 ne in Adult Participants With Ovarian Cancer\nEstimated primary completion
 : January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mirve
 tuximab-soravtansine#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07059845
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05887609-11140@assetmemo.bio
DTSTAMP:20261121T010017Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT05887
 609)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2.\nStudy: An Evalu
 ation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Ola
 parib\nEstimated primary completion: 31 January 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05887609
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06840886-11140@assetmemo.bio
DTSTAMP:20261121T010017Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 1 readout est. (NCT06840
 886)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 1\, Ovarian Cancer.
 \nStudy: A Study of PHST001 in Advanced Solid Tumors\nEstimated primary co
 mpletion: April 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /mirvetuximab-soravtansine#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06840886
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890338-11140@assetmemo.bio
DTSTAMP:20261121T010017Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT06890
 338)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2\, Ovarian Cancer.
 \nStudy: A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infus
 ed Carboplatin With Mirvetuximab Soravtansine in Participants With Newly D
 iagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epit
 helial Ovarian\, Fallopian Tube or Primary Peritoneal Cancer.\nEstimated p
 rimary completion: February 2030. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/mirvetuximab-soravtansine#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06890338
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
